Personalized Autologous Transplant

Personalized Autologous Transplant for Multiple Myeloma

What's the purpose of the trial?

This phase I trial studies the best dose and side effects of melphalan in treating patients with multiple myeloma who are undergoing stem cell transplant. 

Trial status

Accepting patients

Phase
Phase 1
Enrollment
90
Last Updated
4 months ago
Am I Eligible

Participating Centers

There are 2 centers participating in this trial. Enter a location below to find the closest center.

Experimental Treatments

Learn more about the experimental treatments being evaluated in this clinical trial.

  • Autologous Stem Cell Transplant is a type of stem cell transplant that utilizes the patient's own pre-collected stem cells to rescue the bone marrow from the toxic effects of very high dose chemotherapy.
  • Lenalidomide is an oral immunomodulatory drug that may help the immune system kill cancer cells. It may also prevent the growth of new blood vessels that tumors need to grow.
  • Melphalan is a chemotherapy medication used in the treatment of different cancers.
  • Personalized Vaccine Therapy is in development to treat certain kinds of cancer. Personalized Vaccines are made specifically for individual patients, and researchers think they can work by training the patients T-cells to recognize and attack their specific cancer cells.

Arms / Cohorts

Explore eligibility, treatments and learn more about potential cohorts.

Accepting patients

Melphalan-Based Autologous Transplant

Accepting patients

Personalized Vaccine + Lenalidomide

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print a patient-friendly report to share with your patient.

We can help answer any questions and connect you (or your patient) with the study team.

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.